New Study Indicates Quinolone Antibiotics As Main Cause C. Diff Epidemic

A Study recently published in the journal The Lancet Infectious Diseases indicates that overuse of fluoroquinolones may be sole cause of deadly C. Diff Epidemic. Antibiotic overuse can have severe consequences, especially with certain types of antibiotics and this study begins to quantify one of the ways in which this happens and how widespread the harm […]

February 16th, 2017|General News|0 Comments

Canadian National Health Service Safety Review Identifies Serious Quinolone Risks

On January 23, 2017 the national health service of Canada, Health Canada, announced that their recent safety review revealed serious safety issues with fluoroquinolone antibiotics. This follows the 2015 review conducted by the U.S Food & Drug Administration which reached a similar conclusion. The FDA review results were announced on 5/12/2016. In addition to […]

January 28th, 2017|General News|0 Comments

New Fluoroquinolone Formulation in Development

Pulmaquin, an inhaled liposomal ciprofloxacin, is currently undergoing two Phase 3 clinical studies to determine its safety and effectiveness as an inhaled formulation for the treatment of patients with non-cystic fibrosis bronchiectasis, cystic fibrosis or non-tuberculous mycobacteria.

Changing the Tide of Antibiotic-Resistant Infections

January 15th, 2017|General News|0 Comments

The Quinolone Vigilance Foundation 2016 Year in Review

The Quinolone Vigilance Foundation wishes to thank all of our supporters. We had a busy and productive year and we would not be able to do this kind of work without all of our supporters. The Year in Review is posted on our Facebook page: https://www.facebook.com/notes/quinolone-vigilance-foundation/2016-year-in-review/1332337300118474

January 1st, 2017|General News|0 Comments